Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: atrial fibrillation therapy - Devgen

Next Previous
X
Search
Drug Profile

Research programme: atrial fibrillation therapy - Devgen

Alternative Names: CDE 5498; Dev 0304

Latest Information Update: 09 Dec 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Devgen
  • Class
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atrial fibrillation

Most Recent Events

  • 05 Nov 2008 Discontinued - Preclinical for Atrial fibrillation in Belgium (PO)
  • 10 Jul 2008 This programme is still in active development
  • 12 Jan 2006 The programme is available for licensing (http://www.devgen.com)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top